FealtySign in

BAXTER INTERNATIONAL INC

(BAX)

CIK 10456 · SEC filings only

Not gradedDividend record
shown as history
company entity
74 dividend record entries

Dividend record — shown as history, not graded

A declared dividend is a reported fact, not a promise we grade. Here's the record — raises, holds, and cuts — each linked to its source filing.

Dividend record

74 declarations · 14 raised · 56 held · 1 cut · held 3 quarters

  1. HELD$0.0100/shperiod ended 2026-06-30Filing ↗
  2. NOTED$0.0100/shperiod ended 2026-03-31Filing ↗
  3. HELD$0.1700/shperiod ended 2025-09-30Filing ↗
  4. HELD$0.1700/shperiod ended 2025-06-30Filing ↗
  5. CUT$0.1700/shperiod ended 2025-03-31Filing ↗
  6. HELD$0.2900/shperiod ended 2024-09-30Filing ↗
  7. HELD$0.2900/shperiod ended 2024-06-30Filing ↗
  8. HELD$0.2900/shperiod ended 2024-03-31Filing ↗
  9. HELD$0.2900/shperiod ended 2023-11-30Filing ↗
  10. HELD$0.2900/shperiod ended 2023-09-30Filing ↗
  11. HELD$0.2900/shperiod ended 2023-06-30Filing ↗
  12. HELD$0.2900/shperiod ended 2023-03-31Filing ↗
Descriptive dividend record — every entry links to its source filing. Not graded (a declared dividend is a reported fact, not a promise). Full methodology →
Not yet gradedBuyback record
harness minimum not met
company entity
1 resolved promise

Not enough resolved promises to grade

1 of the 4 resolved buyback promises needed to publish a reliability grade. Here's what we're tracking — we never show a grade we can't back with receipts.

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved buyback promises. See the complete multi-year record with Pro.

See Pro →

Credibility timeline

KEPT · Jul 30, 2020
20202020
Timeline as a list
  • Jul 30, 2020KEPTBaxter’s Board of Directors approved a $1.5 billion increase in authorization for the company’s existing share repurchase plan
1 resolved buyback promise · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →
FGuidance record
grade
company entity
42 resolved promises

Resolved promises

Pro

Full say-do history

Free scorecards show the 12 most recent resolved guidance promises. See the complete multi-year record with Pro.

See Pro →

Guidance shown, not graded (81)

These are non-GAAP forecasts. There is no comparable GAAP figure in SEC XBRL to check them against, so we show what was said — with its source filing — but never score it.

  1. eps guidance fy · Jul 30, 2026
    Adjusted earnings from continuing operations per diluted share: $1.95 to $2.15
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  2. revenue guidance fy · Jul 30, 2026
    Organic sales growth from continuing operations: 2% to 3%
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  3. eps guidance fy · Apr 30, 2026
    Adjusted earnings from continuing operations per diluted share: $1.85 to $2.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  4. eps guidance fy · Feb 12, 2026
    Adjusted earnings from continuing operations per diluted share: $1.85 to $2.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  5. eps guidance q · Oct 30, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.52 to $0.57 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  6. eps guidance fy · Oct 30, 2025
    The company now expects adjusted earnings from continuing operations, before special items, of $2.35 to $2.40 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  7. eps guidance q · Jul 31, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.58 to $0.62 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  8. eps guidance fy · Jul 31, 2025
    The company now expects adjusted earnings from continuing operations, before special items, of $2.42 to $2.52 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  9. revenue guidance q · May 1, 2025
    The company expects sales growth from continuing operations of 4% to 5% on a reported basis and 1% to 2% on an operational basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  10. eps guidance fy · May 1, 2025
    The company now expects adjusted earnings from continuing operations, before special items, of $2.47 to $2.55 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  11. eps guidance q · May 1, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.59 to $0.63 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  12. revenue guidance fy · May 1, 2025
    Baxter now expects sales growth from continuing operations of 7% to 8% on a reported basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  13. eps guidance q · Feb 20, 2025
    The company expects adjusted earnings from continuing operations, before special items, of $0.47 to $0.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  14. eps guidance fy · Feb 20, 2025
    expects adjusted earnings from continuing operations, before special items, of $2.45 to $2.55 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  15. revenue guidance fy · Feb 3, 2025
    The company remains committed to its previously announced 2025 financial objectives of 4% to 5% operational sales growth
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  16. eps guidance q · Nov 8, 2024
    The company expects total adjusted earnings, before special items, of $0.77 to $0.81 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  17. eps guidance fy · Nov 8, 2024
    The company expects total company adjusted earnings, before special items, of $2.90 to $2.94 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  18. eps guidance fy · Aug 6, 2024
    The company expects adjusted earnings, before special items, of $2.93 to $3.01 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  19. revenue guidance q · Aug 6, 2024
    and 4% to 5% on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  20. eps guidance q · Aug 6, 2024
    The company expects adjusted earnings, before special items, of $0.77 to $0.79 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  21. revenue guidance fy · Aug 6, 2024
    Baxter now expects sales growth of approximately 3% on both a reported and constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  22. eps guidance q · May 2, 2024
    The company expects adjusted earnings, before special items, of $0.65 to $0.67 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  23. revenue guidance q · May 2, 2024
    The company expects sales growth of approximately 1% on a reported basis and 2% to 3% on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  24. revenue guidance fy · May 2, 2024
    Baxter now expects sales growth of approximately 2% on a reported basis and 2% to 3% on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  25. eps guidance fy · May 2, 2024
    The company expects adjusted earnings, before special items, of $2.88 to $2.98 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  26. eps guidance q · Feb 8, 2024
    The company expects adjusted earnings, before special items, of $0.59 to $0.62 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  27. eps guidance fy · Feb 8, 2024
    The company expects adjusted earnings, before special items, of $2.85 to $2.95 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  28. revenue guidance q · Feb 8, 2024
    The company expects sales growth of approximately 1% on a reported basis and 1% to 2% on a constant currency basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  29. revenue guidance fy · Feb 8, 2024
    Baxter expects sales growth of approximately 2% on both a reported and constant currency basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  30. eps guidance fy · Nov 2, 2023
    The company expects adjusted earnings from continuing operations, before special items, of $2.57 to $2.60 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  31. eps guidance q · Nov 2, 2023
    The company expects adjusted earnings from continuing operations, before special items, of $0.85 to $0.88 per share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  32. eps guidance q · Jul 27, 2023
    The company expects third-quarter adjusted earnings in aggregate (including discontinued operations) of $0.78 to $0.80 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  33. eps guidance fy · Jul 27, 2023
    Baxter expects full-year 2023 adjusted earnings of $2.87 to $2.95 per diluted share in the aggregate (including discontinued operations)
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  34. eps guidance fy · Apr 27, 2023
    adjusted EPS of $2.85 to $3.00
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  35. eps guidance q · Apr 27, 2023
    adjusted earnings, before special items, of $0.59 to $0.61 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  36. eps guidance q · Feb 9, 2023
    adjusted earnings, before special items, of $0.46 to $0.50 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  37. eps guidance fy · Feb 9, 2023
    adjusted earnings, before special items, of $2.75 to $2.95 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  38. eps guidance q · Oct 27, 2022
    adjusted earnings, before special items, of $0.92 to $0.99 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  39. eps guidance fy · Oct 27, 2022
    adjusted earnings, before special items, of $3.53 to $3.60 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  40. eps guidance fy · Jul 28, 2022
    adjusted EPS of $3.60 to $3.70
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  41. eps guidance q · Jul 28, 2022
    adjusted earnings, before special items, of $0.79 to $0.83 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  42. eps guidance q · Apr 28, 2022
    adjusted earnings, before special items, of $0.86 to $0.89 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  43. eps guidance fy · Apr 28, 2022
    adjusted EPS of $4.12 to $4.20
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  44. eps guidance q · Feb 17, 2022
    adjusted earnings, before special items, of $0.79 to $0.82 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  45. eps guidance fy · Feb 17, 2022
    adjusted earnings, before special items, of $4.25 to $4.35 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  46. eps guidance fy · Oct 28, 2021
    adjusted EPS of $3.58 to $3.62
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  47. eps guidance q · Oct 28, 2021
    adjusted earnings, before special items, of $1.00 to $1.04 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  48. eps guidance q · Jul 29, 2021
    adjusted earnings, before special items, of $0.93 to $0.95 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  49. eps guidance fy · Jul 29, 2021
    adjusted EPS of $3.49 to $3.55
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  50. revenue guidance q · Apr 29, 2021
    The company expects sales growth of 14% to 15% on a reported basis, 8% to 9% on a constant currency basis and 7% to 8% on an operational basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  51. revenue guidance fy · Apr 29, 2021
    The company expects sales growth of 8% to 9% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  52. eps guidance q · Apr 29, 2021
    adjusted earnings, before special items, of $0.72 to $0.75 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  53. eps guidance q · Feb 4, 2021
    adjusted earnings, before special items, of $0.63 to $0.65 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  54. eps guidance fy · Feb 4, 2021
    adjusted earnings, before special items, of $3.35 to $3.43 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  55. eps guidance fy · Oct 29, 2020
    adjusted EPS of $3.02 to $3.05
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  56. eps guidance fy · Jul 30, 2020
    adjusted EPS of $3.00 to $3.10
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  57. eps guidance q · Mar 17, 2020
    The company expects adjusted net income, before special items, of $0.72 to $0.74 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  58. eps guidance fy · Jul 25, 2019
    adjusted earnings from continuing operations, before special items, of $3.34 to $3.40 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  59. eps guidance q · Jul 25, 2019
    adjusted earnings from continuing operations, before special items, of $0.82 to $0.84 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  60. eps guidance q · Jan 31, 2019
    The company expects adjusted earnings from continuing operations, before special items, of $0.66 to $0.68 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  61. eps guidance fy · Jan 31, 2019
    The company expects adjusted earnings from continuing operations, before special items, of $3.22 to $3.30 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  62. revenue guidance q · Jul 26, 2018
    The company expects sales growth of approximately 3 percent on a reported basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  63. eps guidance fy · Jul 26, 2018
    The company now expects adjusted earnings from continuing operations, before special items, of $2.94 to $3.00 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  64. revenue guidance fy · Jul 26, 2018
    The company continues to expect sales growth of approximately 5 percent on a constant currency basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  65. eps guidance q · Jul 26, 2018
    The company expects adjusted earnings from continuing operations, before special items, of $0.72 to $0.74 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  66. revenue guidance fy · Jul 26, 2018
    4 to 5 percent on an operational basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  67. revenue guidance fy · Jul 26, 2018
    The company now expects sales growth of approximately 6 percent on a reported basis
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  68. eps guidance fy · Apr 26, 2018
    Baxter expects adjusted earnings from continuing operations, before special items, of $2.85 to $2.93 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  69. eps guidance q · Apr 26, 2018
    The company expects adjusted earnings from continuing operations, before special items, of $0.69 to $0.71 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  70. eps guidance q · Oct 25, 2017
    The company expects earnings from continuing operations, before special items, of $0.56 to $0.59 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  71. eps guidance fy · Oct 25, 2017
    Earnings from continuing operations, before special items, are now expected to be $2.40 to $2.43 per diluted share.
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  72. revenue guidance q · Apr 26, 2017
    Baxter expects underlying constant currency sales growth of approximately 3 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  73. eps guidance fy · Apr 26, 2017
    earnings from continuing operations, before special items, of $2.20 to $2.28 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  74. revenue guidance fy · Apr 26, 2017
    Baxter expects underlying constant currency sales growth of approximately 4 to 5 percent
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  75. eps guidance q · Apr 26, 2017
    The company expects earnings from continuing operations, before special items, of $0.55 to $0.57 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  76. eps guidance q · Oct 25, 2016
    Baxter expects earnings from continuing operations, before special items, of $0.49 to $0.52 per diluted share for the fourth quarter of 2016
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  77. eps guidance fy · Oct 25, 2016
    earnings from continuing operations, before special items, of $1.88 to $1.91 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  78. eps guidance q · Apr 26, 2016
    Baxter expects earnings from continuing operations, before special items, of $0.38 to $0.40 per diluted share for the second quarter of 2016
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  79. eps guidance fy · Apr 26, 2016
    the company now expects earnings from continuing operations, before special items, of $1.59 to $1.67 per diluted share for the full year
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  80. eps guidance q · Oct 27, 2015
    Baxter also expects earnings from continuing operations, before special items, of $0.30 to $0.32 per diluted share for the fourth quarter
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗
  81. eps guidance fy · Oct 27, 2015
    for the second half of 2015, the company now expects earnings from continuing operations, before special items, of $0.71 to $0.73 per diluted share
    Unverifiable — company guides non-GAAP; no comparable GAAP actual exists in XBRL.Filing ↗

Open promises (24) · 30 superseded

Open · revenue guidance q

Baxter expects sales growth of 1 to 2 percent in the fourth quarter of 2015

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

the company expects full-year sales growth of approximately 3 percent

unresolved — no outcome on file$3.0000receipt →
Open · eps guidance q

GAAP earnings from continuing operations for the fourth quarter and second half of $0.23 to $0.25

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Baxter expects sales to increase approximately 1 percent excluding the impact of foreign exchange

unresolved — no outcome on filereceipt →
Open · revenue guidance q

the company expects sales to decline approximately 9 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance q

the company expects constant currency sales growth of approximately 4 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance q

on a reported basis, sales growth of approximately 2 percent

unresolved — no outcome on filereceipt →
Open · revenue guidance q

sales growth of approximately 2 percent on both a reported and constant currency basis

unresolved — no outcome on file$2.0000receipt →
Open · eps guidance q

GAAP earnings of $0.36 to $0.39 per diluted share for the fourth quarter of 2016

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

sales growth of approximately 2 percent on a reported basis or 4 percent on a constant currency basis

unresolved — no outcome on filereceipt →
Open · revenue guidance q

or approximately 2 percent on a constant currency basis

unresolved — no outcome on filereceipt →
Open · revenue guidance q

The company expects flat sales growth on a reported basis

unresolved — no outcome on file$0.0000receipt →
Open · revenue guidance fy

Baxter now expects sales growth of approximately 4 percent on a reported basis, approximately 4 percent on a constant currency basis, and approximately 4 to 5 percent operationally.

unresolved — no outcome on filereceipt →
Open · revenue guidance q

The company expects sales growth of 4 to 5 percent on a reported basis

unresolved — no outcome on filereceipt →
Open · revenue guidance q

The company expects sales to decline approximately 3 percent on a reported basis

unresolved — no outcome on filereceipt →
Open · revenue guidance q

approximately 5% on both a constant currency and operational basis

unresolved — no outcome on filereceipt →
Open · revenue guidance q

The company expects sales growth of 4% to 5% on a reported basis

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Baxter expects full-year 2020 low single digit sales growth on a reported, constant currency and operational basis

unresolved — no outcome on filereceipt →
Open · eps guidance q

The company expects U.S. GAAP earnings of $0.75 to $0.79 per diluted share

unresolved — no outcome on filereceipt →
Open · revenue guidance q

The company expects sales growth of mid-to-high single digits on a reported basis

unresolved — no outcome on filereceipt →
Open · eps guidance q

The company expects U.S. GAAP earnings of $0.60 to $0.67 per diluted share

unresolved — no outcome on filereceipt →
Open · revenue guidance q

The company expects sales to decline low single digits on both a reported basis and constant currency basis.

unresolved — no outcome on filereceipt →
Open · revenue guidance fy

Reported sales growth from continuing operations: 3% to 4%

resolves in ~202 daysreceipt →
Open · revenue guidance fy

Reported sales growth from continuing operations: flat to 1%

resolves in ~202 daysreceipt →
Superseded · revenue guidance fy

Baxter now expects sales growth from continuing operations of 6% to 7% on a reported basis.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter now expects sales to increase approximately 1 percent

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects full-year 2020 sales growth of 4%-5% on both a reported and constant currency basis

revised by a later guidancereceipt →
Superseded · eps guidance fy

The company expects U.S. GAAP earnings of $2.91 to $2.99 per diluted share

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis

revised by a later guidancereceipt →
Superseded · eps guidance fy

$8.94 to $9.06 per diluted share for full-year 2016

revised by a later guidancereceipt →
Superseded · revenue guidance fy

or approximately 4 percent after adjusting for increased U.S. competition for cyclophosphamide

revised by a later guidancereceipt →
Superseded · eps guidance fy

Baxter now expects full-year U.S. GAAP EPS of $2.82 to $2.88

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects sales growth of 7% to 8% on a reported basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

2% to 3% on an operational basis

revised by a later guidancereceipt →
Superseded · eps guidance fy

Baxter now expects full-year U.S. GAAP EPS of $1.82 to $1.92

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects sales growth of 1% to 2% on a reported basis

revised by a later guidancereceipt →
Superseded · eps guidance fy

Baxter expects full-year U.S. GAAP EPS of $2.35 to $2.43

revised by a later guidancereceipt →
Superseded · eps guidance fy

Baxter now expects U.S. GAAP earnings of $2.85 to $2.93 per diluted share

revised by a later guidancereceipt →
Superseded · revenue guidance fy

and 3 to 4 percent on an operational basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects sales growth of 24% to 25% on a reported basis

revised by a later guidancereceipt →
Superseded · eps guidance fy

The company expects U.S. GAAP earnings of $1.43 to $1.63 per diluted share

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Reported sales growth from continuing operations: flat to 1%

revised by a later guidancereceipt →
Superseded · eps guidance fy

Baxter expects full-year U.S. GAAP EPS of $2.40 to $2.50

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects sales growth from continuing operations of 5% to 6% on a reported basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company now expects sales growth of approximately 1 to 2 percent on a reported basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects full-year 2020 reported sales growth between -1% to +1%

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects sales growth of 0 to 1 percent on a reported basis

revised by a later guidancereceipt →
Superseded · eps guidance fy

The company expects U.S. GAAP earnings of $2.91 to $3.01 per diluted share

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects full-year 2023 sales growth from continuing operations of 1% to 2% on a reported basis and approximately 2% on a constant currency basis.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

The company expects sales growth of approximately 8% on a reported basis, 5% to 6% on a constant currency basis and 4% to 5% on an operational basis.

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter now expects constant currency growth for full-year 2016 of approximately 3 percent

revised by a later guidancereceipt →
Superseded · revenue guidance fy

Baxter expects full-year 2023 sales growth of 1% to 2% on a reported basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

4% to 5% on a constant currency basis

revised by a later guidancereceipt →
Superseded · revenue guidance fy

2 to 3 percent on a constant currency basis

revised by a later guidancereceipt →

Credibility timeline

UNRESOLVABLE · Apr 26, 2018UNRESOLVABLE · Apr 26, 2018UNRESOLVABLE · Jan 31, 2019MISSED · Jul 27, 2023MISSED · Jul 27, 2023MISSED · Nov 2, 2023MISSED · Feb 8, 2024MISSED · Feb 8, 2024BEAT · Feb 8, 2024MISSED · Nov 12, 2024MISSED · Feb 21, 2025MISSED · May 6, 2025MISSED · Nov 4, 2025BEAT · Feb 12, 2026BEAT · Feb 12, 2026
20182026
Timeline as a list
  • Apr 26, 2018UNRESOLVABLEThe company expects sales growth of approximately 9 percent on a reported basis
  • Apr 26, 2018UNRESOLVABLEThe company now expects sales growth of approximately 7 to 8 percent on a reported basis
  • Jan 31, 2019UNRESOLVABLEto increase approximately 1 percent on a constant currency basis
  • Jul 27, 2023MISSEDThe company expects sales growth of approximately 1% to 2% on a reported basis
  • Jul 27, 2023MISSEDThe company expects U.S. GAAP earnings of $0.18 to $0.20 per diluted share
  • Nov 2, 2023MISSEDThe company expects third-quarter sales growth from continuing operations of approximately 2% on a reported basis and 1% on a constant currency basis.
  • Feb 8, 2024MISSEDThe company expects sales growth from continuing operations of 1% to 2% on a reported basis
  • Feb 8, 2024MISSEDBaxter expects sales growth from continuing operations of 1% to 2% on a reported basis
  • Feb 8, 2024BEATBaxter expects full-year U.S. GAAP EPS of $1.16 to $1.31
  • Nov 12, 2024MISSEDThe company expects sales growth of 3% to 4% on a reported basis
  • Feb 21, 2025MISSEDBaxter now expects total company sales growth of 1% to 2% on a reported basis
  • May 6, 2025MISSEDThe company expects sales growth from continuing operations of 3% to 4% on a reported basis
  • Nov 4, 2025MISSEDThe company expects sales growth from continuing operations of 6% to 7% on a reported basis
  • Feb 12, 2026BEATBaxter now expects sales growth from continuing operations of 4% to 5% on a reported basis
  • Feb 12, 2026BEATThe company expects sales growth from continuing operations of approximately 2% on a reported basis and a decline of approximately 2% on an operational basis
42 resolved guidance promises · 84dropped (couldn't be resolved on a consistent basis) · resolver resolver-v3 · score score-v1. Every verdict links to its source filing. Full methodology →